$RXRX News

Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5

Recursion Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $8 Price Target

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2026 Earnings Call Transcript

Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss

Recursion Pharmaceuticals Q1 EPS $(0.22) Beats $(0.27) Estimate, Sales $6.472M Miss $15.777M Estimate

Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings?

What Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny Stock

Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts

Recursion Announces Board Transition

JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10

Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell'

Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities

Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast

A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention

Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market